Nasal version of Oxford/AstraZeneca Covid vaccine fails in trial
A nasal version of the Oxford/AstraZeneca Covid-19 vaccine has failed in an early-stage trial, dealing a blow to hopes for...
A nasal version of the Oxford/AstraZeneca Covid-19 vaccine has failed in an early-stage trial, dealing a blow to hopes for...
By Isabel KuaSINGAPORE (Reuters) - Oil prices fell on Tuesday, extending nearly 2% losses in the previous session, as a...
This piece has been adapted from “Plagues and Their Aftermath,” by Brian Michael Jenkins. Pandemics kill millions. Their effects, however, extend...
Back in March 2018, I found my mind wandering inside Beijing’s Great Hall of the People as China’s rubber-stamp parliament...
Study finds boosters give good protection against Omicron hospital casesA US study of almost 17,000 patients finds modest two-dose Pfizer...
The risk of maternal critical care admission and preterm birth were much lower amid dominance of the SARS-CoV-2 Omicron variant...
The Office of Personnel Management is making it a little easier for federal employees to get their booster doses of...
(Reuters) - Attempts by Oxford University researchers and AstraZeneca Plc to create a nasal-spray version of their jointly developed COVID-19...
FRANKFURT, Oct 10 (Reuters) - A Pfizer (PFE.N) executive with a lead role in negotiating a COVID-19 vaccine bulk supply...
Covid: hopes for Oxford nasal vaccine dealt blow after poor trial resultsScientists ditch plans to develop nasal spray version of...